智通财经APP获悉，海西新药(02637)早盘涨超4%，截至发稿，涨3.42%，报148港元，成交额1946.04万港元。
消息面上，海西新药发布公告，HXP056已于2025年7月初启动中国wAMD患者一期临床试验，目前已完成单次给药剂量递增（SAD）与多次给药剂量递增（MAD）阶段全部患者招募，并在连续给药四周后完成剂量限制性毒性（DLT）评估及药代动力学（PK）数据收集；初步疗效评估同步进行中。2025年第四季度，公司已启动二期临床剂量扩展研究。
值得注意的是，自3月9日起，海西新药正式纳入港股通标的名单，符合港股通准入条件的内地投资者可通过沪港通、深港通下的港股通机制，直接交易公司在香港联交所上市的H股。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.